Skip to main navigation
Intercept Pharmaceuticals homepage
  • News
Intercept Pharmaceuticals Logo
Menu
Close✕
  • About Us
    • Leadership
    • News
    • Company Statements
    • OCALIVA: Withdrawal Process
  • Our Focus
    • Meet Ally
    • Patient Resources
  • Our Research
    • FXR
    • Pipeline
    • Medical Information Request Form
  • Careers
    • Job Postings
  • Contact Us
  • Media
Home > Transparency Disclosures

    Transparency Disclosures

    Please refer below to transparency disclosures in local language and with English translation.

    Belgium

    France


    Belgium

    Relations with patient associations
    Relatie met patiëntenverenigingen
    Relations avec les associations de patients
    Zusammenarbeit mit Patientenorganisationen

    Information regarding Intercept’s support for patient associations in Belgium can be found by consulting the Belgian transparency website (https://www.betransparent.be).

    Intercept’s ondersteuning van patiëntenorganisaties in België is te vinden in het Belgische transparantieplatform (https://www.betransparent.be).

    Les informations concernant le soutien d’Intercept aux associations de patients en Belgique peuvent être trouvées en consultant le site de la Transparence belge (https://www.betransparent.be).

    Intercepts Unterstützungen an Patientenorganisationen in Belgien finden Sie auf der Belgischen Transparenzplattform (https://www.betransparent.be).

    Intercept has supported the following patient organizations in Belgium during calendar year 2018. Information about this is subject to change and will be updated from time to time, usually once a year.

    Intercept heeft de volgende patiëntenverenigingen gesteund in België in het jaar 2018. Deze informatie kan veranderen en zal regelmatig bijgewerkt worden, gewoonlijk op jaarlijkse basis.

    Intercept a appuyé les associations de patients suivantes en Belgique pendant l’année civile 2018. Les informations à ce propos sont susceptibles de changer et seront mises à jour de temps à autre, généralement une fois par an.

    Intercept hat im Kalenderjahr 2018 folgende Patientenorganisationen in Belgien unterstützt. Die Informationen sind nicht endgültig und werden von Zeit zu Zeit, in der Regel jährlich, aktualisiert.

    Patiëntenvereniging
    Bedrag
    Doel van de betaling
    European Liver Patients' Association€7,200 Financiële ondersteuning voor standruimte op de EASL NAFLD Summit in september 2018.
    Association de patients
    Montant
    Objet du paiement
    European Liver Patients' Association€7,200 Soutien financier pour le stand réservé lors du congrès EASL NAFLD de septembre 2018.
    Patientenorganisation
    Betrag
    Verwendungszweck
    European Liver Patients' Association€7,200 Finanzielle Unterstützung für Standflächen beim EASL NAFLD-Gipfel im September 2018.

    France

    Access the Transparency-Health public database.
    Accéder à la base de données publique Transparence - Santé.

    • Our Focus
      • Meet Ally
      • Patient Resources
    • Our Research
      • FXR
      • Pipeline
      • Medical Information Request Form
    • About Us
      • Leadership >
      • News >
    • Careers
      • Job Postings
    Intercept Pharmaceuticals Logo
    • Website Privacy Policy
    • Consumer Health Data Privacy Policy
    • EU-US Data Privacy Framework (DPF) Policy
    • Corporate Compliance
    • Terms of Use
    • Contact Us
    • Cookie Preferences
    • Transparency Disclosures
    305 Madison Avenue |Morristown, NJ 07960|T: 1-844-782–4278
    © 2024 Intercept Pharmaceuticals, Inc.
    US-NP-OT-0023
    US-NP-OT-0023

    YOU ARE NOW leaving interceptpharma.com


    You are now leaving Intercept Pharmaceuticals’ corporate website and entering a site intended for U.S. audiences only.

    Continue

    YOU ARE NOW leaving interceptpharma.com


    You are now leaving Intercept Pharmaceuticals’ corporate website. Intercept does not control or endorse the content of this external site.

    Continue

    YOU ARE NOW leaving interceptpharma.com


    You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

    Close this window to return to Intercept Pharmaceuticals’ site or click ‘Continue’ to proceed.

    Continue

    United States (US)
    European Union (EU)
    Canada
    Israel
    Switzerland
    Australia
    Liechtenstein
    United Arab Emirates (UAE)

    Close

    Exploring Racial Differences and Disparities in PBC Care

    Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., has voluntarily withdrawn OCALIVA® (obeticholic acid) from the market for the treatment of primary biliary cholangitis (PBC), effective November 14.

    Patients should talk to their healthcare professionals and may also contact Intercept's patient support services (Interconnect at 1-844-622-4278) through December 31, 2025.

    Healthcare professionals can contact Medical Information at medinfo@interceptpharma.com or 1-844-782-4278. Additionally, patients or healthcare professionals may request Full Prescribing Information or the OCALIVA Medication Guide by contacting medinfo@interceptpharma.com.

    For all other inquiries please contact: info@interceptpharma.com

    Acknowledge